經過評估，專家小組得出結論，在任何使用條件下，都沒有確定東革阿里根提取物作為新型食品的安全性。部分原文報道如下：

 

　　Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on Eurycoma lo ngifolia (To ngkat Ali) root extract as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is standardised water extract prepared from the dried ground root chips of To ngkat Ali (Eurycoma lo ngifolia Jack) and proposed by the applicant to be used as food supplement in amounts up to 200 mg/day. The target population is the adult population, except pregnant and lactating women. The characteristic compo nents of the NF are glycosapo nins (40–65%) and eurycomanone (0.8–1.5%). It can also co ntain canthin-6-one alkaloids and isoscopoletin (coumarin). The NF has been present in various internatio nal markets since 2009. The Panel notes positive results from the submitted in vitro chromosome aberration test, which indicates clastogenic properties of the NF. In the requested follow-up in vivo mammalian alkaline comet assay, the NF induced positive results at the highest dose tested (2,000 mg/kg body weight (bw)) at the tissues of the first site of co ntact (stomach and duodenum). Histopathological e valuation of the tested tissues indicated that the positive results of the comet assay were rather due to genotoxicity than cytotoxicity. Taken together, the Panel co ncludes that the NF has the potential to induce DNA damage, which is of concern, particularly locally for tissues that represent first sites of contact. The Panel co ncludes that the safety of NF has not been established under any co ndition of use.